Summary:
Help ENLIGHTEN MASH/NASH treatment options. Together, let’s find a treatment for MASH/NASH. Consider joining the ENLIGHTEN Fibrosis study, which is researching the investigational drug, pegozafermin.
Summary: The ENLIGHTEN Fibrosis study is a phase 3 clinical trial for people with fatty liver disease, otherwise known as MASH/NASH, studying the effectiveness and safety of the study medication, pegozafermin. This study is for people aged 18-80 who have been confirmed to have MASH/NASH with fibrosis. Together, we aim to provide a potential treatment and improve the lives of people living with MASH/NASH.
Criteria:
- Age 18-80
- Willing to undergo a biopsy of the liver to confirm MASH/NASH and again after 1 year and 3 years of treatment
- Confirmed Diagnosis of MASH/NASH with F2 or F3 Fibrosis